Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP0113 in CMV-seropositive HCT recipients
NCT01877655Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Sep 2013
- Primary completion
- Sep 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 11
01
Overview
A Phase 3 trial of ASP0113 in cytomegalovirus infection (CMV), sponsored by Astellas Pharma. Started Sep 2013; status: completed.
02
Drugs
ASP0113
03
Conditions
cytomegalovirus infection (CMV)
Beyond the preview
Go deeper on NCT01877655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01877655.